Literature DB >> 36204481

Efficacy of Direct Renin Inhibitors in Slowing Down the Progression of Diabetic Kidney Disease: A Meta-Analysis.

Hanieh Akbariromani1, Rushna Haseeb2, Sumreen Nazly3, Sushmita Pandey4, Venkata Anirudh Chunchu5, Sandesh Dhakal6, Mary Anne Claudine Avena7, Neelum Ali8.   

Abstract

Albuminuria is a risk factor for chronic kidney disease and cardiovascular events in diabetic people. The pathogenic processes in these circumstances have been documented to be significantly influenced by enhanced renin-angiotensin system activity. The current meta-analysis was carried out to assess the efficacy of direct renin inhibitors in preventing the progression of diabetic kidney disease. This meta-analysis was conducted as per the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We searched the relevant medical literature through PubMed, Cochrane library and EMBASE. The primary efficacy outcome was a percentage change in urine albumin-creatinine ratio (UACR) (in mg/g) level. Other primary efficacy outcomes included remission from microalbuminuria to normal albuminuria and progression from microalbuminuria to macroalbuminuria. Four randomized control studies were identified and included in the current meta-analysis involving 9,609 participants. The use of direct renin inhibitors was superior in reducing mean UACR compared to angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. The pooled mean difference in UACR between direct renin inhibitors and the control group was 9.42% (95% CI: -15.70 to -3.15: p-value=0.003). The odds of progression from microalbuminuria to normal albuminuria are 1.26 times higher in patients receiving direct renin inhibitors compared to patients in the control group (OR: 1.26, 95% CI: 1.08-1.46, p-value=0.002). The odds of remission from microalbuminuria to macroalbuminuria were 20% lower in patients receiving direct renin inhibitors compared to patients in the control group (OR: 0.80, 95% CI: 0.69-0.93, p-value=0.003). The use of aliskiren is associated with a significant reduction in UACR, increased remission from microalbuminuria to normal albuminuria and decreased progression from microalbuminuria to macroalbuminuria.
Copyright © 2022, Akbariromani et al.

Entities:  

Keywords:  albuminuria; diabetic kidney disease; direct renin inhibitor; meta-analysis; progression

Year:  2022        PMID: 36204481      PMCID: PMC9527562          DOI: 10.7759/cureus.28608

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  22 in total

1.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Temporal trends in the prevalence of diabetic kidney disease in the United States.

Authors:  Ian H de Boer; Tessa C Rue; Yoshio N Hall; Patrick J Heagerty; Noel S Weiss; Jonathan Himmelfarb
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

3.  Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.

Authors:  K J Schjoedt; S Andersen; P Rossing; L Tarnow; H-H Parving
Journal:  Diabetologia       Date:  2004-11-17       Impact factor: 10.122

4.  Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.

Authors:  Piero Ruggenenti; Anna Fassi; Aneliya Parvanova Ilieva; Ilian Petrov Iliev; Carlos Chiurchiu; Nadia Rubis; Giulia Gherardi; Bogdan Ene-Iordache; Flavio Gaspari; Annalisa Perna; Paolo Cravedi; Antonio Bossi; Roberto Trevisan; Nicola Motterlini; Giuseppe Remuzzi
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

5.  Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.

Authors:  Toshiharu Ninomiya; Vlado Perkovic; Bastiaan E de Galan; Sophia Zoungas; Avinesh Pillai; Meg Jardine; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Stephen Macmahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

6.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw
Journal:  Diabetologia       Date:  2010-09-30       Impact factor: 10.122

7.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

8.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

9.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 10.  The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

Authors:  Ziv Harel; Cameron Gilbert; Ron Wald; Chaim Bell; Jeff Perl; David Juurlink; Joseph Beyene; Prakesh S Shah
Journal:  BMJ       Date:  2012-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.